562 related articles for article (PubMed ID: 32826324)
21. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
[TBL] [Abstract][Full Text] [Related]
22. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Walsh M; Merkel PA; Peh CA; Szpirt WM; Puéchal X; Fujimoto S; Hawley CM; Khalidi N; Floßmann O; Wald R; Girard LP; Levin A; Gregorini G; Harper L; Clark WF; Pagnoux C; Specks U; Smyth L; Tesar V; Ito-Ihara T; de Zoysa JR; Szczeklik W; Flores-Suárez LF; Carette S; Guillevin L; Pusey CD; Casian AL; Brezina B; Mazzetti A; McAlear CA; Broadhurst E; Reidlinger D; Mehta S; Ives N; Jayne DRW;
N Engl J Med; 2020 Feb; 382(7):622-631. PubMed ID: 32053298
[TBL] [Abstract][Full Text] [Related]
23. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of protein A immunoadsorption and therapeutic plasma exchange in ANCA-associated vasculitis with severe renal involvement: a retrospective study.
Liu X; Xia M; Liu D; Liu H; Tang C; Chen G; Liu Y; Yuan F; Liu H
Ann Med; 2023 Dec; 55(1):2230875. PubMed ID: 37452682
[TBL] [Abstract][Full Text] [Related]
25. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
[No Abstract] [Full Text] [Related]
26. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
[TBL] [Abstract][Full Text] [Related]
27. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Sejismundo LP; Mieras K; Iklé D; Jepson B; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheum; 2013 Sep; 65(9):2441-9. PubMed ID: 23754238
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series.
Liu L; Lu H; Zou G; Wang H; Li J; Yang Y; Zhang J; Wang X; Li W; Zhuo L
BMC Nephrol; 2023 Feb; 24(1):28. PubMed ID: 36755215
[TBL] [Abstract][Full Text] [Related]
30. Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management.
Plumb LA; Oni L; Marks SD; Tullus K
Pediatr Nephrol; 2018 Jan; 33(1):25-39. PubMed ID: 28062909
[TBL] [Abstract][Full Text] [Related]
31. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
32. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
33. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
Alberici F; Jayne DR
Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
[TBL] [Abstract][Full Text] [Related]
34. [State of art and new perspectives in the induction regimen of ANCA-associated vasculitis with renal involvement: from histopathology to therapy].
Uzzo M; Alberici F
G Ital Nefrol; 2021 Feb; 38(1):. PubMed ID: 33599423
[TBL] [Abstract][Full Text] [Related]
35. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
36. Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy.
Gérard M; de Boysson H; Morello R; Martin-Silva N; Leroux AC; Dumont A; Maigné G; Boutemy J; Khoy K; Mariotte D; Lobbedez T; Aouba A; Deshayes S
Scand J Rheumatol; 2023 Mar; 52(2):161-173. PubMed ID: 35048797
[TBL] [Abstract][Full Text] [Related]
37. How best to manage relapse and remission in ANCA-associated vasculitis.
Puéchal X; Guillevin L
Expert Rev Clin Immunol; 2022 Nov; 18(11):1135-1143. PubMed ID: 36102147
[TBL] [Abstract][Full Text] [Related]
38. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
[TBL] [Abstract][Full Text] [Related]
39. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Iklé D; Villarreal M; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheumatol; 2014 Nov; 66(11):3151-9. PubMed ID: 25047592
[TBL] [Abstract][Full Text] [Related]
40. ANCA-associated vasculitis in scleroderma: A renal perspective
.
Kant S; Shah AA; Hummers LK; Wigley FM; Geetha D
Clin Nephrol; 2018 Dec; 90(6):413-418. PubMed ID: 30106367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
